Table 1.
Design for study 1a
| Randomized sequence group | Period 1 |
Period 2 |
||||
|---|---|---|---|---|---|---|
| Days 1–10 | Days 11–13 | Day 14 | Days 1–10 | Days 11–13 | Day 14 | |
| Sequence 1 | Treatment A | Treatment C | Treatment E | Treatment B | Treatment D | Treatment F |
| Sequence 2 | Treatment B | Treatment D | Treatment F | Treatment A | Treatment C | Treatment E |
| Day(s) of PK data collection | 1, 9, 10 | 11, 13 | 14 | 1, 9, 10 | 11, 13 | 14 |
a
A ≥14-day washout was used between periods 1 and 2. Treatment A, lersivirine at 1,000 mg q.d. plus rifampin at 600 mg q.d.; treatment B, lersivirine at 1,000 mg q.d. plus placebo; treatment C, lersivirine at 1,000 mg BID plus rifampin at 600 mg q.d.; treatment D, lersivirine at 1,000 mg BID plus placebo; treatment E, lersivirine at 1,000 mg plus rifampin at 600 mg q.d.; treatment F, lersivirine at 1,000 mg plus placebo.